Management of Severe Asthma before Referral to the Severe Asthma Specialist

被引:25
作者
Carr, Tara F. [1 ]
Kraft, Monica [1 ]
机构
[1] Univ Arizona, Asthma & Airway Dis Res Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA
基金
美国国家卫生研究院;
关键词
Biologic therapy; Comorbidities; Adherence; Inhaled corticosteroid; Phenotype; Severe asthma; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; FORCED EXPIRATORY FLOW; VOCAL CORD DYSFUNCTION; BETA-AGONIST TREATMENT; QUALITY-OF-LIFE; ENVIRONMENTAL ASSESSMENT; DOUBLE-BLIND; MEDICATION ADHERENCE; IMPULSE OSCILLOMETRY; MONOCLONAL-ANTIBODY;
D O I
10.1016/j.jaip.2017.04.027
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Severe asthma is associated with significant morbidity and can be challenging to assess and control, due to heterogeneity of disease, complexity of diagnosis, and impact of comorbidities. A structured approach to the assessment and management of severe asthma may be helpful to the practicing clinician. First, it is important to confirm a diagnosis of asthma. In patients who are either not responding to treatment, or who require high doses of medication to control symptoms, it is highly possible that disease mimickers or comorbidities are present and can inhibit therapeutic responsiveness. The assessment and management of common comorbidities of asthma may dramatically impact disease control and thus medication requirement. Determining medication adherence and optimizing drug dose and delivery may separate out truly severe asthmatics from those not using medications regularly or properly. Next, although true personalized medicine for severe asthma is not yet realized, for those individuals with severe asthma, phenotypic characteristics of each patient may guide which therapeutic options may be most effective for that patient. Finally, evaluation and management of severe asthma at a referral center can add additional phenotyping, therapeutic, and diagnostic strategies. (C) 2017 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:877 / 886
页数:10
相关论文
共 101 条
[1]   Effect of asthma therapies on the natural course of asthma [J].
Abrams, Elissa M. ;
Szefler, Stanley J. ;
Becker, Allan B. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (06) :627-633
[2]  
Agarwal R, 2009, INT J TUBERC LUNG D, V13, P936
[3]   Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis [J].
Agarwal, Ritesh ;
Sehgal, Inderpaul S. ;
Dhooria, Sahajal ;
Aggarwal, Ashutosh N. .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (12) :1317-1334
[4]  
Akinbami Lara J, 2012, NCHS Data Brief, P1
[5]   TH17-associated cytokines (IL-17A and IL-17F) in severe asthma [J].
Al-Ramli, Wisam ;
Prefontaine, David ;
Chouiali, Fazila ;
Martin, James G. ;
Olivenstein, Ron ;
Lamiere, Catherine ;
Hamid, Qutayba .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (05) :1185-1187
[6]   Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases [J].
Alagha, Khuder ;
Palot, Alain ;
Sofalvi, Tunde ;
Pahus, Laurie ;
Gouitaa, Marion ;
Tummino, Celine ;
Martinez, Stephanie ;
Charpin, Denis ;
Bourdin, Arnaud ;
Chanez, Pascal .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2014, 5 (02) :85-98
[7]   Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase® [J].
Aldea Perona, Ana ;
Garcia-Saiz, Mar ;
Sanz Alvarez, Emilio .
DRUG SAFETY, 2016, 39 (01) :69-78
[8]  
[Anonymous], 2015, GLOB STRAT ASTHM MAN
[9]   Home Assessment and Remediation [J].
Barnes, Charles S. ;
Horner, W. Elliott ;
Kennedy, Kevin ;
Grimes, Carl ;
Miller, J. David .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2016, 4 (03) :423-+
[10]   ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS IN CORTICOSTEROID-DEPENDENT ASTHMATICS [J].
BASICH, JE ;
GRAVES, TS ;
BAZ, MN ;
SCANLON, G ;
HOFFMANN, RG ;
PATTERSON, R ;
FINK, JN .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1981, 68 (02) :98-102